The development of newer agents such as raltegravir, etravirine and maraviroc has improved the perspective of viral load suppression. However, there is not enough data regarding their use together. In this study, we describe nine patients who were triple-class experienced and were on a salvage regimen consisting of a combination of raltegravir, etravirine, and maraviroc. Our results showed that this regimen is safe with no major side effect and has good virological efficacy with twothirds of the patients achieving an undetectable viral load by 24 weeks.
Although the advent of newer antiretroviral (ARV) medications has improved the perspective of viral load suppression, one of the main remaining challenges is the development of antiretroviral resistance. [1] [2] [3] The need for new ARV medications to combat drug resistance will be ever present until an HIV cure is developed. The present standard of care in antiretroviral administration is a regimen containing at least 2, preferably 3, fully active medications. This is most commonly accomplished by using 2 nucleoside reverse transcriptase inhibitors (NRTIs) and either a protease inhibitor (PI) or a nonnucleoside reverse transcriptase inhibitor (NNRTI). 4 Within the past few years, 2 new classes of ARV medications and a new agent in the NNRTI class have been approved by the US Food and Drug Administration (FDA): the CCR5 receptor antagonist maraviroc (MVC), the inhibitors of HIV integrase, raltegravir (RAL), and the NNRTI, and etravirine (ETR). [5] [6] [7] These 3 agents have been used in combination with other active ARV medications to create potent, fully suppressive regimens. 8 However, in some patient populations, the only remaining fully active ARV medications are these 3 agents. This case-series reviews patients from a large HIV patient cohort that were treated with these 3 agents in combination and reports on the tolerability and effectiveness of this regimen.
We conducted a retrospective review of 6000 current patients on HIV therapy to generate a list of charts to review by searching the electronic medical records for patients on MVC, RAL, and ETR in combination. Salvage therapy was prescribed according to: viral tropism, screening genotype, and previous resistance testing. The data was reviewed and analyzed at baseline and at week-24. Our inclusion criteria were (1) evidence of virological failure and/or resistance to at least 3 classes of antiretroviral medication, (2) the presence of R5-trophic virus at baseline, (3) the use of a regimen containing MVC, RAL, ETR together, (4) available data for evaluation at baseline and at 24 weeks, and (5) integrase inhibitor naivety.
Nine patients met these criteria (7 males and 2 females). These patients had a mean age of 50 years (range: 34-62). The mean time that these patients had been receiving ARV medications was 12.3 years. All of the patients were at least triple-class experienced with multiple mutations on the HIV genotypes as described in Table 1 . The median ETV mutation score for the 9 patients was approximately 1.5 (range 0-3.5; Table 1 ).
Of the 9 patients, 3 were on a regimen of MVC 600 mg twice-daily (BID), RAL 400 mg BID, ETR 200 mg BID (group 1, N ¼ 3), and the remaining 6 patients taking the above-mentioned regimen were also receiving tenofovir 300 mg once daily (group 2, N ¼ 1), tenofovir/emtricitabibe 300 mg/200 mg once daily (group 3, N ¼ 4), and abacavir/ lamivudine 600 mg/300 mg once daily (group 4, N ¼ 1). The median baseline CD4 counts for the 4 treatment groups were 119 cells/mm 3 (range: 83-546 cells/mm 3 ), 184 cells/mm 3 (range: 19-268 cells/mm 3 ), 734 cells/mm 3 , and 434 cells/mm 3 for groups 1 through 4, respectively. Also, the baseline HIV viral load for the 4 groups were 5.2 log10 copies/mL (range: 5.0-5.6 copies/mL), 4.85 log10 copies/mL (range: 2.3-5.5 copies/ mL), 2.6 log10 copies/mL, and 4.0 log10 copies/mL for groups 1 through 4, respectively (see Table 2 ). At week 24, the average CD4 count was 285 cells/mm 3 . The 4 treatment groups had the following average CD4 counts at week 24; 389 cells/mm 3 , 219 cell/mm 3 , 630 cells/mm 3 , and 467 cells/mm 3 for groups 1 through 4, respectively. Also, the treatment groups had the following average HIV viral load at week 24; <1.68 log10 copies/mL, 2.61 log10 copies/mL, 2.06 log10 copies/mL, and <1.68 log10 copies/mL for groups 1 through 4, respectively. The percentage of patients achieving HIV-RNA levels <400 copies/mL and <50 copies/mL at week 24 was 78% (7/9) and 67% (6/9), respectively. In the 2 patients that did not achieve <400 copies/mL HIV-RNA levels, poor ARV adherence was documented. All patients tolerated this regimen well with no discontinuation due to adverse events up to 24 weeks.
Based on these results, salvage therapy with RAL þ MVC þ ETR showed excellent CD4 recovery and HIV-RNA suppression at 24 weeks after starting this combination regimen. One unique aspect of this combination are the drug-drug interactions between ETR and MVC causing a decreased concentration of maraviroc requiring dosing at 600 mg BID rather than the standard 300 mg BID. Providers must be cognizant of this interaction when initiating this regimen. The combination of RAL, MVC, and etravirne appears safe and highly efficacious in the management of HIV-treatmentexperienced patients.
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